home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc.

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...
XRTX - XORTX Announces Publication of Key Research in ADPKD

CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...

XRTX - Money Talk Radio with Ellis Martin: XORTX Therapeutics Inc. (NASDAQ:XRTX) Dr. Allen Davidoff-Look for More M&As in the Kidney Disease Remediation Space in the Future

Malibu, CA, United States (ABN Newswire) - In this segment of Money Talk Radio with Ellis Martin, we speak with Dr. Allen Davidoff, CEO of XORTX Therapeutics (NASDAQ:XRTX) (CVE:XRTX), a pioneer in developing new therapies for progressive kidney disease and diabetes. Recently Vertex Pharmaceut...

XRTX - XORTX Announces Participation in Spring 2024 Investor Conferences

CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive...
XRTX - XORTX Announces New Clinical Advisory Board Member

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ) , a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney...

XRTX - XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial

(NewsDirect) New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage...

XRTX - XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...
XRTX - XORTX Reprices Warrants Issued in Connection with Previous Private Placements

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 11, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a la...

XRTX - Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack

2024-03-07 09:09:27 ET CERo Therapeutics ( CERO ) +625% after announces publication of preclinical research supporting the use of its clinical candidate CER-1236 to treat AML patients . Lytus Technologies ( LYT ) +210% after enters $326 billion data center market...

XRTX - BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers

2024-03-06 10:00:12 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
Next 10